Archives

Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting

B BOSTON, April 16, 2026 /PRNewswire/ —  Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing brain-penetrant small molecule therapies for neurodegenerative diseases, today announced… Login to continue reading Login…

Read MoreBrenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing

B Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners… Login to continue reading Login…

Read MorePiramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing